Depomed Announces Allowance Of U.S. Patent Covering Gastric Retentive Gabapentin Dosage Forms
Links shared publicly online about this topic.
- 1,409total visits
Depomed Announces Allowance Of U.S. Patent Covering Gastric Retentive Gabapentin Dosage Forms
Depomed, Inc. (NASDAQ:DEPO) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a U.S. patent application (No. 12/239,591) directed to pharmaceutical
View full resource at medicalnewstoday.com
Tags: Menopause, Migraine Prevention Medication, Seizure Medication, Pharma, Women's Health, Neurontin, Epilepsy Medication
Most Recently Shared on February 3, 2010 at 2:16 pm By:
Depomed Announces Allowance Of U.S. Patent Covering Gastric Retentive Gabapentin Dosage Forms http://mnt.to/3x7y #menopause
Advertisement
